- Home
- OVID vs CRIS Comparison
OVID vs CRIS Comparison
Compare OVID & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- CRIS
- Stock Information
- Founded
- OVID 2014
- CRIS 2000
- Country
- OVID United States
- CRIS United States
- Employees
- OVID N/A
- CRIS N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVID Health Care
- CRIS Health Care
- Exchange
- OVID Nasdaq
- CRIS Nasdaq
- Market Cap
- OVID 20.6M
- CRIS 22.9M
- IPO Year
- OVID 2017
- CRIS 2000
- Fundamental
- Price
- OVID $1.23
- CRIS $1.68
- Analyst Decision
- OVID Strong Buy
- CRIS Strong Buy
- Analyst Count
- OVID 4
- CRIS 2
- Target Price
- OVID $3.13
- CRIS $16.50
- AVG Volume (30 Days)
- OVID 2.0M
- CRIS 72.4K
- Earning Date
- OVID 08-13-2025
- CRIS 08-05-2025
- Dividend Yield
- OVID N/A
- CRIS N/A
- EPS Growth
- OVID N/A
- CRIS N/A
- EPS
- OVID N/A
- CRIS N/A
- Revenue
- OVID $6,651,000.00
- CRIS $11,405,000.00
- Revenue This Year
- OVID $708.13
- CRIS $1.41
- Revenue Next Year
- OVID N/A
- CRIS $7.46
- P/E Ratio
- OVID N/A
- CRIS N/A
- Revenue Growth
- OVID 1070.95
- CRIS 12.24
- 52 Week Low
- OVID $0.24
- CRIS $1.02
- 52 Week High
- OVID $1.47
- CRIS $6.44
- Technical
- Relative Strength Index (RSI)
- OVID 70.64
- CRIS 48.15
- Support Level
- OVID $1.16
- CRIS $1.63
- Resistance Level
- OVID $1.30
- CRIS $1.95
- Average True Range (ATR)
- OVID 0.11
- CRIS 0.14
- MACD
- OVID 0.01
- CRIS 0.02
- Stochastic Oscillator
- OVID 78.00
- CRIS 43.75
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.